Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|14|9|835-841

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.14, Iss.9, 2013-10, pp. : 835-841

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

By  

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

By Saraceni Christine   Broderick Tom L.  

Drugs in R&D, Vol. 8, Iss. 3, 2007-01 ,pp. : 145-153

Adis International

Access to resources Recommend Favorite

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

By Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

European Journal of Pharmacology, Vol. 451, Iss. 2, 2002-09 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite